Soft tissue sarcoma (STS) is a family of malignancies for which individual management decisions can be complex. There is a paucity of level 1 evidence, as the rarity and heterogeneity of STS pose challenges to the design and execution of randomized controlled trials. Radiotherapy (RT) is routinely used to facilitate function-preserving surgery and to improve local control. Delivery of RT in the preoperative setting can decrease chronic toxicities at the cost of increased wound complications in the short-term. The role of adjuvant systemic therapies remains controversial in adult STS.
Keywords: Chemotherapy; Extremity sarcoma; Preoperative radiotherapy; Randomized controlled trial; Retroperitoneal sarcoma; Soft tissue sarcoma.
Copyright © 2017 Elsevier Inc. All rights reserved.